Teva Pharmaceutical Industries has secured approval for generic Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the US and is in the last stages of launch preparation.
The firm also recently secured approval and launched generic Azor (amlodipine and olmesartan medoxomil) tablets in the US.
These products expand Teva’s anti-hypertensive portfolio.
Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of an angiotensin II receptor blocker, a dihydropyridine calcium channel blocker and a thiazide diuretic meant to treat hypertension and lower blood pressure.
Amlodipine and olmesartan medoxomil tablets are a dihydropyridine calcium channel blocker and angiotensin II receptor blocker combination product meant for the treatment of hypertension, either alone or with other antihypertensive agents to reduce blood pressure.
Reducing blood pressure cuts down the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
Several patients will need more than one drug to meet their blood pressure goals.
Teva stated that it is committed to bolstering its generics business through continued investment in complex, high-quality products.
With nearly 600 generic medicines available, the firm has the largest portfolio of
It also has more than 300 product registrations pending
One in six generic prescriptions currently dispensed in the US is filled with a Teva generic product, the company claimed.